Patent · US Active

siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)

US7592442B2 · kind B2 · utility

51Cited by
10References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 13, 2007
Grant dateSep 22, 2009
Priority date
Expiry dateAug 14, 2027

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2330/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to RRM 2.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.